Haibing He - Search Results

Year	Number of Results
2006	5
2007	3
2008	2
2009	1
2010	11
2011	13
2012	12
2013	3
2014	8
2015	6
2016	12
2017	19
2018	25
2019	15
2020	24
2021	33
2022	27
2023	24
2024	8

1

Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.

Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, Zhang Y, Tang X, Wu R. Xue Y, et al. Among authors: he h. Expert Opin Drug Deliv. 2021 Feb;18(2):187-203. doi: 10.1080/17425247.2021.1825376. Epub 2020 Oct 5. Expert Opin Drug Deliv. 2021. PMID: 32954856 Review.

2

Silica nanoparticles on the oral delivery of insulin.

Tan X, Liu X, Zhang Y, Zhang H, Lin X, Pu C, Gou J, He H, Yin T, Zhang Y, Tang X. Tan X, et al. Among authors: he h. Expert Opin Drug Deliv. 2018 Aug;15(8):805-820. doi: 10.1080/17425247.2018.1503250. Epub 2018 Jul 25. Expert Opin Drug Deliv. 2018. PMID: 30025216 Review.

3

The interplay between PEGylated nanoparticles and blood immune system.

Guo C, Yuan H, Wang Y, Feng Y, Zhang Y, Yin T, He H, Gou J, Tang X. Guo C, et al. Among authors: he h. Adv Drug Deliv Rev. 2023 Sep;200:115044. doi: 10.1016/j.addr.2023.115044. Epub 2023 Aug 2. Adv Drug Deliv Rev. 2023. PMID: 37541623 Review.

4

Inflammation-responsive molecular-gated contact lens for the treatment of corneal neovascularization.

Sun R, Ma S, Chen X, Deng Y, Gou J, Yin T, He H, Wang Y, Tang X, Zhang Y. Sun R, et al. Among authors: he h. J Control Release. 2023 Aug;360:818-830. doi: 10.1016/j.jconrel.2023.07.036. Epub 2023 Jul 25. J Control Release. 2023. PMID: 37481212

5

Biopharmaceutical characters and bioavailability improving strategies of ginsenosides.

Pan W, Xue B, Yang C, Miao L, Zhou L, Chen Q, Cai Q, Liu Y, Liu D, He H, Zhang Y, Yin T, Tang X. Pan W, et al. Among authors: he h. Fitoterapia. 2018 Sep;129:272-282. doi: 10.1016/j.fitote.2018.06.001. Epub 2018 Jun 5. Fitoterapia. 2018. PMID: 29883635 Review.

6

Recent advances in nanoscale metal-organic frameworks for cancer chemodynamic therapy.

Ji M, Liu H, Gou J, Yin T, He H, Zhang Y, Tang X. Ji M, et al. Among authors: he h. Nanoscale. 2023 May 25;15(20):8948-8971. doi: 10.1039/d3nr00867c. Nanoscale. 2023. PMID: 37129051 Review.

7

Environmental explanation of prostate cancer progression based on the comprehensive analysis of perfluorinated compounds.

Wei Y, He H, Han T, Wang B, Ji P, Wu X, Qian J, Shao P. Wei Y, et al. Among authors: he h. Ecotoxicol Environ Saf. 2023 Sep 15;263:115267. doi: 10.1016/j.ecoenv.2023.115267. Epub 2023 Jul 25. Ecotoxicol Environ Saf. 2023. PMID: 37499384 Free article.

8

Asymmetric Synthesis of Rugulotrosin A.

Chen J, Li Y, Xiao Z, He H, Gao S. Chen J, et al. Among authors: he h. Org Lett. 2020 Feb 21;22(4):1485-1489. doi: 10.1021/acs.orglett.0c00063. Epub 2020 Feb 10. Org Lett. 2020. PMID: 32037839

9

Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies.

Sun W, Deng Y, Zhao M, Jiang Y, Gou J, Wang Y, Yin T, Zhang Y, He H, Tang X. Sun W, et al. Among authors: he h. J Control Release. 2021 May 10;333:41-64. doi: 10.1016/j.jconrel.2021.01.010. Epub 2021 Jan 12. J Control Release. 2021. PMID: 33450321 Review.

10

Progress and prospects of polysaccharide-based nanocarriers for oral delivery of proteins/peptides.

Yuan H, Guo C, Liu L, Zhao L, Zhang Y, Yin T, He H, Gou J, Pan B, Tang X. Yuan H, et al. Among authors: he h. Carbohydr Polym. 2023 Jul 15;312:120838. doi: 10.1016/j.carbpol.2023.120838. Epub 2023 Mar 24. Carbohydr Polym. 2023. PMID: 37059563 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

226 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Results by year